

AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

Please cancel claims 3 and 4 without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): A method for treating an occult ~~[[a]]~~ choroidal neovascular (CNV) lesion in a subject comprising providing photodynamic therapy (PDT) to a subject assessed as having either or both of (a) a small lesion with a size less than about 4-5 disc areas or (b) poor visual acuity of less than about 65 letters prior to treatment.

Claim 2 (Original): The method of claim 1 wherein said subject was assessed by determining the size of said lesion and/or determining the best corrected visual acuity of the subject.

Claims 3-4 (Canceled)

Claim 5 (Original): The method of claim 1 wherein the small lesion has a size less than about 4 disc areas.

Claim 6 (Original): The method of claim 1, wherein the occult CNV is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).

Claim 7 (Original): The method of claim 1 wherein said PDT comprises the administration of a photosensitizer (PS).

Claim 8 (Original): The method of claim 7, wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m² (PS/body surface area of subject).

Claim 9 (Original): The method of claim 8, wherein the PS is administered at a concentration of 6 mg/m^2 .

Claim 10 (Original): The method of claim 9, wherein the PS is a green porphyrin.

Claim 11 (Original): The method of claim 10, wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.

Claim 12 (Original): The method of claim 11, wherein the green porphyrin is BPD-MA.

Claim 13 (Original): The method of claim 10, wherein the PS is coupled to a specific binding ligand.

Claim 14 (Original): The method of claim 7, wherein the PS is formulated with a carrier.

Claim 15 (Original): The method of claim 14, wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.

Claim 16 (Original): The method of claim 1, wherein said PDT comprises irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.

Claim 17 (Original): The method of claim 16, wherein the irradiation provides between 12.5 J/cm^2 and 100 J/cm^2 .

Claim 18 (Original): The method of claim 17, wherein said irradiation occurs between 5 to 30 minutes after administration of a photosensitizer.

Claim 19 (Original): The method of claim 7, wherein the PS is administered at a concentration ranging between about $10 \text{ } \mu\text{g/kg}$ to 100 mg/kg (PS/body weight of subject).